Form 8-K - Current report:
SEC Accession No. 0001104659-24-107327
Filing Date
2024-10-09
Accepted
2024-10-09 16:08:22
Documents
15
Period of Report
2024-10-03
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2425903d1_8k.htm   iXBRL 8-K 27855
2 EXHIBIT 10.1 tm2425903d1_ex10-1.htm EX-10.1 37220
3 EXHIBIT 10.2 tm2425903d1_ex10-2.htm EX-10.2 63984
  Complete submission text file 0001104659-24-107327.txt   329079

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA btai-20241003.xsd EX-101.SCH 3048
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE btai-20241003_lab.xml EX-101.LAB 34240
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE btai-20241003_pre.xml EX-101.PRE 22381
17 EXTRACTED XBRL INSTANCE DOCUMENT tm2425903d1_8k_htm.xml XML 3562
Mailing Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511
Business Address 555 LONG WHARF DRIVE NEW HAVEN CT 06511 203-643-8060
BioXcel Therapeutics, Inc. (Filer) CIK: 0001720893 (see all company filings)

EIN.: 821386754 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38410 | Film No.: 241362865
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)